WitFW, KesselringAM, GrasL. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.Clin Infect Dis2008; 46: 933–40.
2.
De LazzariE, LeonA, ArnaizJA. Risk of hepatotoxicity in virologically suppressed HIV patients switching to nevirapine according to gender and CD4 count.Antiviral Therapy2006; 11: L8.
3.
SchoutenJ, KrambrinkA, RibaudoH. Substitution of nevirapine [NVP] for efavirenz [EFV] toxicity in ACTG A5095.Abstract presented at the 48th annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, 25-28 October 2008, Washington, DC, USA (Abstract H-1236).
4.
MocroftA, PhillipsAN, SorianoV. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection.AIDS Res Hum Retroviruses2005; 21: 743–52.
5.
HurwitzSJ, AsifG, KivelNM, SchinaziRF. Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model.Antimicrob Agents Chemother2008; 52: 4241–50.
